Estrogen receptor ␣ (ER␣) is a ligand-regulated transcription factor with a broad range of physiological functions and one of the most important classifiers in breast cancer. MicroRNAs (miRNAs) are small noncoding RNAs that have emerged as important regulators of gene expression in a plethora of physiological and pathological processes. Upon binding the 3 untranslated region (UTR) of target mRNAs, miRNAs typically reduce their stability and/or translation. The ER␣ mRNA has a long 3 UTR of about 4.3 kb which has been reported to reduce mRNA stability and which bears evolutionarily conserved miRNA target sites, suggesting that it might be regulated by miRNAs. We have performed a comprehensive and systematic assessment of the regulatory role of all miRNAs that are predicted to target the 3 UTR of the ER␣ mRNA. We found that miR-22 represses ER␣ expression most strongly and by directly targeting the ER␣ mRNA 3 UTR. Of the three predicted miR-22 target sites in the 3 UTR, the evolutionarily conserved one is the primary target. miR-22 overexpression leads to a reduction of ER␣ levels, at least in part by inducing mRNA degradation, and compromises estrogen signaling, as exemplified by its inhibitory impact on the ER␣-dependent proliferation of breast cancer cells.The steroid hormone 17-estradiol (E2) regulates a number of developmental and physiological processes, such as growth and differentiation, in a range of tissues, including the male and female reproductive tracts, breast epithelium, and a plethora of other organs (9, 23). These physiological effects are mediated, at least in part, by two nuclear receptors, estrogen receptor ␣ (ER␣) and ER. Upon binding E2, they are activated as transcription factors and regulate target genes by binding directly to specific regulatory sequences or indirectly to other DNA-bound transcription factors (23). In addition, rapid nongenomic effects of E2 can be elicited by the same ERs as membrane-associated receptors (22). ER␣ is the more widely expressed of the two ER isoforms, and its levels are regulated by multiple mechanisms in a development-and tissue-specific manner (23). ER␣ levels are regulated at all levels of gene expression, beginning with transcriptional control by several transcription factors (48) and continuing with regulation at the posttranscriptional (26, 27) and posttranslational levels (2), including the control of protein turnover (44).Breast cancer is the most frequent form of cancer in women, and ER␣ is still the most important classifier of breast tumors. ER␣-positive tumors, which represent nearly 70% of all breast tumors, respond to E2 for growth and survival, and consequently, ER␣-positive tumors can be inhibited with antiestrogens such as tamoxifen. Why and how most tumors eventually become resistant to antiestrogen therapy and why some tumors do not express ER␣ from the outset remain hotly debated questions. Multiple mechanisms have been invoked to explain